期刊文献+

Tie2介导的基因导入系统转导p53基因对肺癌的抑制作用 被引量:3

Inhibition of lung cancer by transfer of p53 gene using Tie2-mediated gene delivery system
下载PDF
导出
摘要 目的:探讨Tie2介导的基因导入系统体内靶向转导p53基因治疗肺癌的效果。方法:应用双功能交联剂SMCC将Tie2配体寡肽GA3与PEI连接构建靶向Tie2的基因载体。体外试验将GA3-PEI/luciferase导入Tie2表达阳性的SPC-A1肺癌细胞与Tie2表达阴性的SMMC7721肝癌细胞中,24 h后检测luciferase活性。体内导入试验将GA3-PEI/β-gal复合物注射SPC-A1细胞裸鼠种植瘤周围皮下,同时设立PEI/β-gal组为对照;24 h后牺牲裸鼠,检测心、肝、脾、肺、肾和瘤体的β-gal表达。另外将另一批四周龄SPC-A1肺癌种植瘤裸鼠随机分为5组:(1)NS;(2)GA3;(3)p53;(4)PEI/p53;(5)GA3-PEI/p53;每组6只;皮下注射GA3-PEI/p53基因复合物,隔2天1次,并测量肿瘤长短径,计算瘤体积及抑瘤率。结果:GA3-PEI/luciferase组的luciferase活性在SPC-A1细胞中明显高于SMMC7721细胞(P<0.05)。在种植瘤中可见较多蓝染细胞,心、肝、脾、肾组织中几乎不见篮染,肺支气管黏膜除外。与对照组比较,GA3-PEI/p53治疗组对肿瘤生长有明显抑制作用(P<0.05),其抑瘤率为61.29%。结论:GA3基因导入系统靶向转导p53基因,显著抑制肿瘤生长。 Objective: To explore the therapeutic efficacy of transduction ofp53 gene with Tie2-mediated gene delivery system in the treatment of lung cancer and provide experimental basis for future clinical application. Methods: GA3, a small peptide against Tie 2, was conjugated with PEI by bifunctional crosslinking agent SMCC to construct Tie2-targeted gene vector. Then pCMV-luciferase eDNA was combined with GA3-PEI to form an electrostatic complex. GA3-PEI/lueiferase eDNA complex was transduced into Tie2- positive SPC-A1 lung cancer cells and Tie2-negative SMMC7721 hepatic cancer cells in vitro. The activity of luciferase was measured 24 h later. The GA3-PEI/β-gal complex was injected into peri-tumorous tissues of the transplanted SPC-Al tumors in nude mice in vivo. Meanwhile, PEI/β-gal gene was injected as control. The nude mice were decapitated 24 h later. The heart, liver, spleen, lung, kidney and tumor tissues were excised and stained with X-gal. Human lung cancer SPC-Al cells were inoculated subcutaneously into the 4- week-old female athymie mice (BALB/e). The mice were randomly divided into 5 groups ( NS, GA3, p53, PEI/p53, and GA3-PEI/ p53) with 6 mice in each group. GA3-PEI/p53 1 μg was subcutaneously injected into peri-tumorous tissues once every two days. The tumor volume was calculated according to formula (V = πab2/6). The tumor-inhibiting ratio was calculated regarding NS group as control. Results: The activity of luciferase of GA3-PEI/luciferase was significantly higher in SPC-Al cells than that in SMMC7721 cells (P 〈 0.05 ). A lot of blue-stained cells were observed in transplanted tumor tissues but not in heart, liver, spleen, and kidney tissues except lung bronchial mueosa. Compared with NS group, GA3-PEI/p53 significantly inhibited the growth of tumor by 61.29%. Conclusion: Transfer of p53 gene byGA3 gene delivery system remarkably inhibits tumor growth.
出处 《肿瘤》 CAS CSCD 北大核心 2007年第4期256-259,共4页 Tumor
基金 国家973高科技研究和发展计划资助项目(编号:2004CB518802)
关键词 肺肿瘤 基因疗法 基因P53 受体 TIE-2 遗传载体 Lung neoplasms Genes p53 Receptor,Tie-2 Gene therapy Genetic vectors
  • 相关文献

参考文献9

  • 1JEMAL A,MUNAY T,SAMUELS A,et al.Cancer statistics[J].CA Cancer J Clin,2003,53(1):5-26.
  • 2WU X,ZHAO R,LI Z,et al.A novel small peptide as a targeting ligand for receptor tyrosine kinase Tie2[J].Biochem Biophys Res Commun,2004,315(4):1004-1010.
  • 3WALTHER F J,DAVID-CU R,SUPNET M C,et al.Safety of airway gene transfer with Ad2/CFTR2:Aersol administration in the nonhuman primate[J].Hum Gene Ther,1997,8(4):411-422.
  • 4WU G Y,WU C H.Receptor-mediated in vivo gene transformation by a souble DNA carrier system[J].J Biol Chem,1987,262(10):4429-4432.
  • 5FUJIWARA T,CAI D,GEORGES R,et al.Therapeutical effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model[J].J Natl Cancer Inst,1994,86 (19):1458-1462.
  • 6ZHANG W,FANG X,MAZUR W,et al.High-efficiency gene transfer and high level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus[J].Cancer Gene Ther,1994,1(1):5-13.
  • 7GILLES D,JEAN L M,MRIEL B H,et al.In vivo growth inhibitory effect of iterative wild-type p53 gene transfer in human head and neck carcinoma xenografts using glucosylated polyethylenimine nonviral vector[J].Cancer Gene Ther,2002,(9):708-714.
  • 8SWISHER S,ROTH J,NEMUNAITIS J,et al.Adenovirus-mediated p53 gene transfer in advanced non-small cell lung cancer[J].J Natl Cancer Inst,1999,91 (5):763-771.
  • 9KUBBA S,ADAK S,SCHILLER J.Phase Ⅰ trial of adenovirus p53 in bronchioloalveolar cell lung carcinoma (BAC) administered by bronchoalveolar lavage[J].Proc Am Soc Clin Oncol,2000,1994(4):487.

同被引文献30

  • 1熊斌,雷志勇,陈虹.熊果酸药理学的研究进展[J].国外医学(药学分册),2004,31(3):133-136. 被引量:74
  • 2CHAN K, KYO Y, YONGGOO K, el al. Epstein-Barr virus infection, drug resistance and prognosis in Korean T- and NK-cell lymphomas[ J]. Pathol Int, 2001,51 (5) :355-363.
  • 3POETA M L, MANOLA J, GOLDWASSER M A,et al. TP 53 mutation and survival in squamous cell carcinoma of the head and neck [ J ]. N Engl J Med,2007,357 (25) :2552-2561.
  • 4KESHELAVA N,ZUO J J , CHEN P,et al. Loss of p53 function confers high level multidrug resistance in neuroblastoma cell lines [J].Cancer Res,2001,61(16) :6185-6193.
  • 5KASTAN M B, BARTEK J. Cell-cycle check-points and cancer [J]. Nature,2004,432(7015) :316-323.
  • 6HAINAUT P , HOLLSTEIN M. p53 and human cancer :the first ten thousand mutalions[J].Adv Cancer Res,2000,77 ( 11 ) : 81 - 137.
  • 7HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B, et al. p53 mutation in human cancers [ J ]. Science, 1991,253 ( 5015 ) : 49- 53.
  • 8VAN DYKE T. p53 and tumor suppression [ J ]. N Engl J Med, 2004,356( 1 ) :79-81.
  • 9SINGH B, REDDY P G, GOBERDHAN A, et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas[J].Genes Dev, 2002,16(8) :984-993.
  • 10PAL S, DATTA K, MUKHOPADHYAY D. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma [J]. Cancer Res, 2001,61 ( 18 ) :6952-6957.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部